Source: Cambridge Independent

Morphogen-IX: Morphogen-IX: £18.4m boost for PAH medicine

Pulmonary arterial hypertension (PAH) investment for preclinical trials of disease-modifying MGX292 drug candidate

Read full article »
Morphogen-IX's Competitors | Morphogen-IX's News | Morphogen-IX's Financials
Stay up-to-date with the latest news on Morphogen-IX
Est. Annual Revenue
$100K-5.0M
Est. Employees
1-25
Nick Morrell's photo - Founder & CEO of Morphogen-IX

Founder & CEO

Nick Morrell

CEO Approval Rating

83/100

Read more
Stay up-to-date with the latest news on Morphogen-IX